A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Stopped early · Phase 1
Conditions studied: Non-Small Cell Lung Cancer, Ovarian Cancer, Fallopian Tube Cancer, Triple Negative Breast Cancer, Multiple Myeloma, Pancreatic Ductal Adenocarcinoma
In brief
Multi-center, open-label, first in human Phase 1 study of the safety, tolerability, feasibility, and preliminary efficacy of the administration of genetically modified autologous T cells (CART-TnMUC1 cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen, TnMUC1 and activating the T cell (CART- TnMUC1 cells).
Key facts
- Study ID
- NCT04025216
- Run by
- Kite, A Gilead Company
- People needed
- 16
- Starts
- 2019-10-10
- Expected to finish
- 2022-12-02
- Last updated by the study team
- 2024-01-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic of Arizona — Phoenix, Arizona, United States
- The Angeles Clinic and Research Institute — Los Angeles, California, United States
- Moffitt Cancer Center — Tampa, Florida, United States
- University of Chicago Medical Center — Chicago, Illinois, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- Hospital of the University of Pennsylvania — Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
- The University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- University of Washington Medical Center — Seattle, Washington, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.